Valuation: Simulations Plus, Inc.

Market Cap 372M 325M 299M 278M 528M 35.38B 536M 3.58B 1.39B 17.39B 1.39B 1.36B 59.93B P/E 2026 *
44x
P/E 2027 * 40.6x
Enterprise Value 372M 325M 299M 278M 528M 35.38B 536M 3.58B 1.39B 17.39B 1.39B 1.36B 59.93B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 4.31x
Free-Float
82.79%
Yield 2026 *
-
Yield 2027 * -
1 day-0.19%
1 week-0.08%
Current month+0.30%
1 month+15.43%
3 months+47.39%
6 months-4.70%
Current year+0.74%
1 week 18.27
Extreme 18.27
18.68
1 month 15.64
Extreme 15.64
18.68
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.44
Extreme 7.44
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
16/06Fiscal year

Executive/Senior Manager

22,050 0.1094%
15/06Fiscal year

Executive/Senior Manager

3,150 0.0156%
03/06Sell

Executive/Senior Manager

-1,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-0.08%+9.12%-55.52% 372M
-1.90%+8.10%-32.21%-2.49% 31.31B
+1.97%+8.27%-31.04%+233.65% 15.19B
-1.12%+7.42%-16.78%+65.59% 5.91B
+2.31%-16.01% - - 2.41B
-1.23%+3.90% - - 2.23B
+0.92%+5.65%+49.48%-38.46% 1.96B
-3.11%-15.09%-30.20% - 1.14B
-1.55%+6.69%-33.16%+273.33% 826M
-1.21%+0.62%+552.00%+1,064.29% 756M
Average -0.49%+4.54%+58.40%+220.06% 6.21B
Weighted average by Cap. -0.56%+14.31%-19.55%+85.11%

Financials

2026 *2027 *
Net sales 81.71M 71.43M 65.64M 61.19M 116M 7.78B 118M 788M 306M 3.82B 307M 300M 13.18B 86.2M 75.35M 69.25M 64.55M 122M 8.21B 124M 831M 323M 4.03B 324M 317M 13.9B
Net income 9.02M 7.89M 7.25M 6.76M 12.82M 859M 13.01M 87.02M 33.83M 422M 33.87M 33.14M 1.46B 9.71M 8.49M 7.8M 7.27M 13.79M 924M 14M 93.64M 36.4M 454M 36.44M 35.66M 1.57B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
07/07/26 USD 18.36 -0.16% 59,597
02/07/26 USD 18.39 +0.22% 483,048
01/07/26 USD 18.35 +0.22% 359,532
30/06/26 USD 18.31 -0.38% 872,617
29/06/26 USD 18.38 +0.99% 660,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.39USD
Average target price
17.25USD
Spread / Average Target
-6.20%

Quarterly revenue - Rate of surprise